| Name | UK-101 |
| Description | UK-101 is a potent and selective inhibitor of the immunoproteasome LMP2, inhibiting β1i (LMP2), β1c (LMP2), and β5 (LMP2), with IC50s of 104 nM, 15 μM, and 1 μM, respectively. UK-101 exhibits a 144-fold and 10-fold higher affinity for β1i than for the distribution of β1c and β5 subunits. UK-101 induces apoptosis and can be used to study prostate cancer-related diseases. |
| In vitro | In the G1 phase of the cell cycle, UK-101 (2-8 μM; 24 hours) induces cell cycle arrest and increases the number of the PC-3 cell arrest.UK-101 (1-8 μM; 24 hours) induces cell accumulation in the G1 phase of the cell cycle, it increases p27 accumulation and significantly increases PARP cleavage as a dose-dependent manner.[1] |
| In vivo | Tumor volume as a dose-dependent manner decreased by UK-101 (1-3 mg/kg; twice a week; 3 weeks)intraperitoneal injection, it significantly decreases tumor volume at a dose of 3 mg/kg. Additionally, UK-101-treated mice are suffering less systemic toxicity and the weights of mice treated with UK-101 remain steady over the 3-week treatment period.[1] |
| Storage | 02 | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 3.3 mg/mL (6.81 mM), Sonication is recommended.
DMSO : 237.5 mg/mL (489.95 mM), Sonication is recommended.
|
| Keywords | UK-101 | LMP2 | immunoproteasome β5 | immunoproteasome β1c |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Bioactive Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
